Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2021.840551 Oncology Correction Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients Li Jun 1 2 † Han Sile 1 † Zhang Cuiyun 1 2 Luo Yanlin 3 Wang Li 3 Wang Ping 4 Wang Yi 5 Xia Qingxin 5 Wang Xiaoyan 1 2 Wei Bing 1 2 Ma Jie 1 2 Li Hongle 1 2 * Guo Yongjun 1 2 * 1 Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China 2 Henan Key Laboratory of Molecular Pathology, Zhengzhou, China 3 Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China 4 Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, China 5 Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Yongjun Guo, guoyongjun@zzu.edu.cn; Hongle Li, llhl73@163.com

This article was submitted to Gynecological Oncology, a section of the journal Frontiers in Oncology

†These authors have contributed equally to this work and share first authorship

 14 01 2022 2021 11 840551 21 12 2021 22 12 2021 Copyright © 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: Identification of BRCA1: c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients by Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2021). Front. Oncol. 11:655709. doi: 10.3389/fonc.2021.655709 BRCA1/2 haplotype analysis ovarian cancer founder mutation Chinese

In the original article, we neglected to include the funder National Natural Science Foundation of China, 81802779 to Jun Li; Henan Provincial Health Commission, SBGJ202002020 to Jun Li; and Henan Science and Technology Project, 212102310675 to Jun Li.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.